Trials / Unknown
UnknownNCT00913016
Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole Therapy
Assessment of Quality of Life, Bone Density and Safety in Postmenopausal Breast Cancer Patients With Letrozole (Femara) as an Early Adjuvant Treatment
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 897 (estimated)
- Sponsor
- Korean Breast Cancer Study Group · Academic / Other
- Sex
- Female
- Age
- 45 Years
- Healthy volunteers
- Not accepted
Summary
To compare the overall QoL (Quality of Life) using Trial Outcome index (TOI) of FACT-B questionnaire for 3 years from baseline.
Detailed description
1. TOI is the sum of the scores from the physical and functional well-being and the breast cancer subscales. 2. To assess incidence of adverse events (including cardiovascular, cerebrovascular, and endocrine, musculoskeletal) in Korean postmenopausal breast cancer patients in early adjuvant setting. 3. To assess the effect of letrozole (Femara) on BMD in early adjuvant setting. 4. To assess the effect of letrozole (Femara) on total cholesterol in early adjuvant setting.
Conditions
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2009-06-03
- Last updated
- 2010-02-17
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00913016. Inclusion in this directory is not an endorsement.